Penumbra (PEN) Projected to Post Quarterly Earnings on Thursday

Penumbra (NYSE:PEN - Get Free Report) is expected to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $0.88 per share for the quarter. Penumbra has set its FY 2025 guidance at EPS.Individual that wish to register for the company's earnings conference call can do so using this link.

Penumbra (NYSE:PEN - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $315.52 million for the quarter, compared to analyst estimates of $311.63 million. On average, analysts expect Penumbra to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Penumbra Price Performance

Shares of PEN stock traded down $10.60 during trading hours on Friday, reaching $292.52. 635,327 shares of the company were exchanged, compared to its average volume of 492,793. Penumbra has a fifty-two week low of $148.00 and a fifty-two week high of $310.00. The stock's fifty day moving average is $259.09 and its two-hundred day moving average is $228.23. The company has a market cap of $11.27 billion, a price-to-earnings ratio of 860.35, a P/E/G ratio of 2.83 and a beta of 0.53. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25.

Insider Buying and Selling at Penumbra

In other news, Director Harpreet Grewal sold 167 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total transaction of $40,293.76. Following the completion of the sale, the director now owns 8,530 shares of the company's stock, valued at $2,058,118.40. This represents a 1.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Johanna Roberts sold 600 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $244.49, for a total transaction of $146,694.00. Following the sale, the executive vice president now directly owns 63,444 shares of the company's stock, valued at $15,511,423.56. This represents a 0.94 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 18,219 shares of company stock valued at $4,426,439. Corporate insiders own 5.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Citigroup upped their target price on shares of Penumbra from $220.00 to $245.00 and gave the stock a "neutral" rating in a research report on Wednesday, December 11th. UBS Group upped their target price on shares of Penumbra from $305.00 to $320.00 and gave the stock a "buy" rating in a research report on Wednesday. Royal Bank of Canada upped their target price on shares of Penumbra from $285.00 to $313.00 and gave the stock an "outperform" rating in a research report on Wednesday. Needham & Company LLC restated a "hold" rating on shares of Penumbra in a report on Wednesday. Finally, Piper Sandler restated an "overweight" rating and issued a $330.00 price objective (up from $250.00) on shares of Penumbra in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Penumbra currently has an average rating of "Moderate Buy" and an average target price of $292.64.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.